Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
Disorders of Hemostasis01:24

Disorders of Hemostasis

2.7K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.7K
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

822
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
822
Coagulation01:09

Coagulation

8.4K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
8.4K
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

6.0K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.0K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

482
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
482

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A novel transdermal curcumin gel shows potential in improving cardiac bioenergetic functions in Berkeley sickle cell mice.

Blood vessels, thrombosis & hemostasis·2026
Same author

Thrombophilia, hypofibrinolysis and osteonecrosis.

Orthopadie (Heidelberg, Germany)·2025
Same author

Biopreservation and reversal of oxidative injury during blood storage by a novel curcumin-based gel formulation.

Scientific reports·2024
Same author

Stretch-Induced Spin-Cast Membranes Based on Semi-Crystalline Polymers for Efficient Microfiltration.

Polymers·2024
Same author

Turner's Syndrome, Glucagon-like Peptide 1, and Glucose-dependent Insulinotropic Polypeptide Agents: Silver Bullets?

The Journal of clinical endocrinology and metabolism·2024
Same author

Adsorbent-Embedded Polymeric Membranes for Efficient Dye-Water Treatment.

Polymers·2024
Same journal

Pampiniform venous plexus thrombosis in a 37 years-old male patient with severe thrombocytosis: a multifactorial aetiology.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis·2026
Same journal

PROS1 Cys475Tyr mutation associated with a type III protein S deficiency pattern.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis·2026
Same journal

Dynamic microclot profiling: thromboelastography advances precision management in long COVID and myalgic encephalomyelitis/chronic fatigue syndrome.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis·2026
Same journal

Genetic characterization of Glanzmann thrombasthenia: insights from novel igta2b mutations in a Tunisian patient cohort.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis·2026
Same journal

Uterine fibroids as an underrecognized risk factor for venous thromboembolism: a narrative review.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis·2026
Same journal

SEER sonorheometry enhances fibrinolysis detection during liver transplantation with heparin.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis·2026
See all related articles

Related Experiment Video

Updated: May 1, 2026

Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis
08:50

Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis

Published on: January 9, 2026

392

Testosterone, thrombophilia, thrombosis.

Charles J Glueck1, Joel Friedman, Ahsan Hafeez

  • 1aThrombosis Center bInternal Medicine Residency Program, Jewish Hospital of Cincinnati, Cincinnati, Ohio, USA.

Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis
|April 16, 2014
PubMed
Summary
This summary is machine-generated.

Testosterone therapy can increase the risk of blood clots, including deep venous thrombosis and pulmonary embolism, in men with underlying thrombophilia. Pre-treatment screening for clotting disorders is recommended before starting testosterone.

More Related Videos

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization
06:28

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization

Published on: June 4, 2020

6.4K
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.9K

Related Experiment Videos

Last Updated: May 1, 2026

Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis
08:50

Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis

Published on: January 9, 2026

392
Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization
06:28

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization

Published on: June 4, 2020

6.4K
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.9K

Area of Science:

  • Endocrinology
  • Hematology
  • Thrombosis Research

Background:

  • Testosterone (T) therapy is increasingly used, but its association with thrombotic events is not fully understood.
  • Undiagnosed thrombophilia-hypofibrinolysis may predispose individuals to thrombosis when initiating T therapy.

Purpose of the Study:

  • To assess the prevalence of thrombophilia-hypofibrinolysis in men who developed thrombosis while taking testosterone.
  • To investigate the interaction between testosterone therapy and thrombophilia in the development of venous thromboembolism (VTE).

Main Methods:

  • Retrospective case-control study involving 11 men with thrombosis post-testosterone initiation.
  • Comparison with healthy male controls and healthy men on testosterone therapy.
  • Laboratory assessment of thrombophilia markers including Factor VIII, Factor V Leiden, plasminogen activator inhibitor-1, prothrombin gene mutation, protein S, and Factor XI.

Main Results:

  • Nine of 11 men (82%) experienced deep venous thrombosis (DVT) or pulmonary embolism (PE) after a median of 3.5 months on testosterone.
  • Significantly higher prevalence of high Factor VIII (36% vs. 2%, P=.005) and Factor V Leiden heterozygosity (18% vs. 0%, P=.04) in T-taking men with thrombosis compared to controls.
  • Recurrent thrombosis occurred in 3 of 11 men despite anticoagulation, indicating a strong interaction between testosterone and thrombophilia.

Conclusions:

  • Testosterone therapy interacts with thrombophilia-hypofibrinolysis, leading to a significant increase in thrombosis risk.
  • Men developing thrombosis while on testosterone should be evaluated for thrombophilia.
  • Continuation of testosterone in thrombophilic men is contraindicated due to high risk of recurrent thrombosis; pre-treatment screening is advised.